NASDAQ:VERU Veru (VERU) Stock Price, News & Analysis $0.85 -0.03 (-3.42%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.84▼$0.8850-Day Range$0.77▼$1.0452-Week Range$0.36▼$1.92Volume265,337 shsAverage Volume1.92 million shsMarket Capitalization$124.16 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Veru alerts: Email Address Veru MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside371.6% Upside$4.00 Price TargetShort InterestBearish8.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.30) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.52 out of 5 starsMedical Sector652nd out of 910 stocksPharmaceutical Preparations Industry299th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingVeru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVeru has received no research coverage in the past 90 days.Read more about Veru's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.91% of the outstanding shares of Veru have been sold short.Short Interest Ratio / Days to CoverVeru has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Veru has recently decreased by 2.47%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERU. Previous Next 1.1 News and Social Media Coverage News SentimentVeru has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Veru this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Veru to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veru insiders have not sold or bought any company stock.Percentage Held by Insiders14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Veru's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veru are expected to grow in the coming year, from ($0.30) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Veru's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” About Veru Stock (NASDAQ:VERU)Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.Read More VERU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERU Stock News HeadlinesSeptember 4 at 8:54 AM | msn.comThe power of music raises awareness of the impact of Knife CrimeSeptember 4 at 8:54 AM | msn.comCross county collaboration through the power of music raises awareness of the impact of Knife CrimeSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 19, 2024 | msn.comBeing ‘very demure’ is TikTok’s newest trend. Here’s what it meansAugust 17, 2024 | finance.yahoo.comVERU Aug 2024 3.000 call (VERU240823C00003000)August 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Veru (VERU) and ACADIA Pharmaceuticals (ACAD)August 11, 2024 | finance.yahoo.comEarnings Beat: Veru Inc. (NASDAQ:VERU) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsAugust 10, 2024 | seekingalpha.comVeru Inc. (VERU) Q3 2024 Earnings Call TranscriptSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 10, 2024 | finance.yahoo.comVeru Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsAugust 10, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Veru (VERU)August 8, 2024 | globenewswire.comVeru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial ResultsAugust 7, 2024 | markets.businessinsider.comOptimal Title Unavailable: Report Summary Not ProvidedAugust 5, 2024 | ca.finance.yahoo.comVERU Aug 2024 3.000 callAugust 5, 2024 | ca.finance.yahoo.comVERU Aug 2024 1.500 callAugust 3, 2024 | msn.comPolice discover giant knife in Bedford estate as part of countywide crackdownAugust 1, 2024 | globenewswire.comVeru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024July 29, 2024 | globenewswire.comVeru to Participate in the BTIG Virtual Biotechnology ConferenceSee More Headlines Receive VERU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Fiscal Year End9/30/2024Next Earnings (Estimated)12/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPersonal Products Current SymbolNASDAQ:VERU CUSIP31446210 CIK863894 Webwww.veruhealthcare.com Phone(305) 509-6897Fax312-595-9122Employees230Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+371.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,150,000.00 Net Margins-376.38% Pretax Margin-259.52% Return on Equity-115.99% Return on Assets-66.94% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.16 Sales & Book Value Annual Sales$16.30 million Price / Sales7.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book3.26Miscellaneous Outstanding Shares146,380,000Free Float125,597,000Market Cap$124.16 million OptionableOptionable Beta-0.48 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Mitchell S. Steiner F.A.C.S. (Age 63)M.D., Chairman, President & CEO Comp: $885.32kDr. Harry Fisch F.A.C.S. (Age 65)M.D., Vice Chairman & Chief Corporate Officer Ms. Michele Greco (Age 65)CFO & Chief Administrative Officer Comp: $493.7kDr. K. Gary Barnette Ph.D. (Age 56)Chief Scientific Officer Comp: $676.27kMr. Samuel FischExecutive Director of Investor Relations & Corporate CommunicationsMr. Michael J. PurvisExecutive VP, General Counsel & Corporate Strategy and SecretaryMr. Kevin J. Gilbert CPAJ.D., Executive Vice President of Corporate DevelopmentMr. Martin Tayler (Age 55)Executive Vice President of FC2 Global Operations Comp: $180.51kMr. Philip R. Greenberg J.D.Executive VP & Deputy General CounselDr. Domingo Rodriguez M.D. (Age 62)Executive Vice President of Global Clinical Operations More ExecutivesKey CompetitorsNu Skin EnterprisesNYSE:NUSNature's Sunshine ProductsNASDAQ:NATRMedifastNYSE:MEDEstée Lauder CompaniesNYSE:ELInter ParfumsNASDAQ:IPARView All CompetitorsInsiders & InstitutionsPVG Asset Management CorpBought 563,155 shares on 8/22/2024Ownership: 0.385%Perceptive Advisors LLCBought 1,478,578 shares on 8/16/2024Ownership: 4.825%Squarepoint Ops LLCBought 191,519 shares on 8/14/2024Ownership: 0.131%Blair William & Co. ILBought 20,000 shares on 8/12/2024Ownership: 0.239%Choreo LLCBought 240,134 shares on 8/7/2024Ownership: 0.227%View All Insider TransactionsView All Institutional Transactions VERU Stock Analysis - Frequently Asked Questions How have VERU shares performed this year? Veru's stock was trading at $0.72 at the start of the year. Since then, VERU shares have increased by 17.8% and is now trading at $0.8482. View the best growth stocks for 2024 here. How were Veru's earnings last quarter? Veru Inc. (NASDAQ:VERU) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The company had revenue of $3.95 million for the quarter, compared to analyst estimates of $3.50 million. Veru had a negative trailing twelve-month return on equity of 115.99% and a negative net margin of 376.38%. Who are Veru's major shareholders? Top institutional shareholders of Veru include Perceptive Advisors LLC (4.83%), Rosalind Advisors Inc. (1.84%), PVG Asset Management Corp (0.38%) and Bank of New York Mellon Corp (0.30%). Insiders that own company stock include Mitchell Shuster Steiner, Harry Fisch, K Gary Barnette and Mario Eisenberger. View institutional ownership trends. How do I buy shares of Veru? Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI) and Vaxart (VXRT). This page (NASDAQ:VERU) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veru Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veru With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.